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ABSTRACT
Objective: This exploratory study aimed to evaluate and compare the treatment costs of taxane-based versus cisplatin-based chemotherapy.
Methods: This study used data from the medical and financial records of ovarian cancer patients who were admitted to Dharmais National 
Cancer Hospital (RSKD) between 2008 and 2012 and subsequently underwent surgery and were treated with chemotherapy. Data were analyzed 
using descriptive analysis, and a Kaplan–Meier graph was plotted to compare the survival of the patients in the taxane-based and cisplatin-based 
chemotherapy groups.
Results: Of 41 patients, treatment costs were available for nine patients who had undergone taxane-based chemotherapy and for 31 patients who had 
undergone cisplatin-based chemotherapy. In general, surgical procedures accounted for the highest proportion of the treatment costs, followed by 
chemotherapy. Taxane-based chemotherapy (six cycles) was 4 times more expensive than cisplatin-based therapy. The pre- and post-chemotherapy 
costs of care among those treated with the taxane-based regimen were 3-4 times more expensive than those of the patients who received cisplatin-
based treatment. The disease-free recurrence duration of the patients treated with taxane was longer (median=18 months) than that of the patients 
treated with cisplatin (median=5 months).
Conclusions: Taxane-based therapy increased the disease-free recurrence duration of the patients, with disease-free recurrence 3 times longer than 
that of the patients treated with the cisplatin-based regimen. However, the treatment costs of the taxane-based regimen were 4 times higher than 
those of the cisplatin-based treatment.
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INTRODUCTION
Epithelial ovarian cancer remains the most lethal gynecologic 
malignancy in the world [1-3]. The global incidence of ovarian cancer 
is approximately 190,000 cases/year and varies depending on the 
country, with 15-20 cases/100,000 in developed countries (i.e., U.S. and 
U.K.), 8-10 cases/100,000 in Southern Europe, and <7 cases/100,000 
in China and Japan [4]. The number of cases in developing countries, 
such as Indonesia, is undetermined due to a lack of registration data [5]. 
However, ovarian cancer is estimated to be the second most common 
gynecological cancer after cervical cancer [6].
The 5-year survival rate of ovarian cancer patients in Indonesia is 
estimated to be between 34.5% and 54.8%, according to data from 
Cipto Mangunkusumo National Referral Hospital [6] and Dharmais 
National Cancer Hospital [7]. Although most ovarian cancer 
patients have a positive response for surgery and chemotherapy [8], 
recurrence occurs in 60-70% of cases within 3 years [9]. The median 
disease-free survival of patients with Stage III disease in Western 
European countries ranges between 15 and 17 months, whereas the 
median disease-free survival of patients with Stage IV disease in these 
countries is 8-9 months [10].
Surgery and chemotherapy remain the standard treatments for Stage 
IC ovarian cancer and higher [11]. Chemotherapy regimens have led 
to improvements in patient outcomes [11]. As reported by Cristea 
et al. [11], monotherapy, which was developed in the 1960s, resulted in a 
response in 13-30% of patients. Monotherapy was followed in the 1980s 
by combination therapy with cisplatin and cyclophosphamide [11]. The 
latter was associated with a positive response in 60% of patients [11]. 
Taxane, introduced in the 1990s, showed the best response (70%) [11]. 
Before 2006, a combination of cisplatin and cyclophosphamide was 
used for ovarian cancer in Dharmais Cancer Hospital. After 2006, 
the treatment protocol for ovarian cancer at the hospital changed 
to cisplatin- and taxane-based regimens [12]. Although these 
chemotherapy regimens are commonly used for ovarian cancer, no cost 
evaluations of these treatments have been conducted.
METHODS
This was an explorative retrospective cohort study aimed at analyzing 
the unit cost components of inpatient care. The study population 
consisted of patients with epithelial ovarian cancer who were admitted 
to Dharmais Cancer Hospital between 2008 and 2012, underwent a 
complete treatment program based on the hospital’s protocol, and 
had a minimum follow-up of 2 years, in addition to a complete medical 
and billing record. Patients with incomplete treatment were excluded 
due to difficulties in assessing outcomes. The exposed group consisted 
of patients who received taxane-based chemotherapy, and the non-
exposed group consisted of patients who received cisplatin-based 
chemotherapy.
Forty-one patients fulfilled the inclusion and exclusion criteria. Three 
patients with complete cost records who underwent surgery and 
cisplatin-based chemotherapy and nine patients who underwent 
surgery and taxane-based chemotherapy were selected. As this 
was an explorative study, data on only about 30% of cases in each 
chemotherapy group were analyzed due to their feasibility, not due to 
their representativeness.
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To obtain surgery costs, data were collected on 13 patients who 
underwent surgery only. This was done due to the difficulty in obtaining 
surgery only costs on the patients who underwent both surgery and 
chemotherapy. However, the characteristics of the patients who 
underwent surgery only were similar to those who underwent both 
surgery and chemotherapy, as the surgery procedure in both groups 
adhered to standard protocols adopted at Dharmais Cancer Hospital.
Patients’ medical data were obtained from their medical records. The 
data included age, education level, insurance, parity, cancer stage, 
complete/incomplete surgery, hemoglobin, albumin, Ca125 presurgery 
levels, and cancer recurrence. Surgery-related costs included operating 
theater, intensive care unit/high care unit, ward, drug, examination 
of surgical specimen, laboratory test, and blood transfusion costs. 
Chemotherapy-related costs included pre- and post-chemotherapy 
expenses. These included the chemotherapy regimen, drugs for 
treating side effects and complications, ward fees, doctors’ fees, and any 
supporting material costs.
Statistical analysis
A descriptive analysis of the cost-related data was conducted. 
A Kaplan–Meier graph was plotted to compare the survival of the 
patients in the taxane-based and cisplatin-based chemotherapy groups.
RESULTS
As shown in Table 1, the patients who received cisplatin-based 
chemotherapy were younger (median: 42 years) than those who 
received taxane-based chemotherapy (median: 51 years). The 
hemoglobin level of more than half of the patients in the taxane group 
(81.3%) was above 10 g/dL, whereas it exceeded this level in only 
18.8% of the patients in the cisplatin group.
In general, surgical procedures accounted for the highest treatment 
costs among all the cost components (pre-chemotherapy, chemotherapy, 
and post-chemotherapy). In the surgical subcomponent, the costs 
for operating rooms, medical personnel, and medicine accounted for 
the highest costs. The total cost of the surgery was approximately 
IDR 80-97 million. Operating room costs accounted for the highest 
proportion (23.4%) of the total costs, followed by operational costs 
for doctors (20%, approximately IDR 22.8 million), medicine(15-
20%,approximately IDR 12-20 million), intensive/high care unit 
or ward (7.5%, approximately IDR 5.8 million), and finally, medical 
consumable materials (3%).
The second highest cost incurred after surgery was the cost of 
chemotherapy. The highest subcomponent cost of chemotherapy 
was the medicine/regimen. The cost of each cycle of taxane-based 
chemotherapy was approximately IDR 7.1 million (53% from 
13.4 million). The cost of each cycle of cisplatin-based chemotherapy 
was IDR 1.5 million (50% from 3.1 million). Six cycles of taxane-based 
chemotherapy were approximately 4 times more expensive than 
cisplatin-based chemotherapy, with a cost of IDR 80 million for the 
former compared to IDR 18 million for the latter. The pre- and post-
chemotherapy costs of the care of those treated with the taxane-based 
Table 1: Characteristic of the ovarian cancer patients
Variables Type of chemotherapy Total p
n (%)
Cisplatin (n=9) Taxane (n=31)
Age (years), mean 45.9±4.5 50.3±1.0
Age (years), median 42 51
Min–max 35-77 40-62
Age group (years)
≤50 7 (33.3) 14 (66.7) 21 0.083
51-60 1 (5.9) 16 (94.1) 17
>60 1 (50) 1 (50) 2
Education level
Secondary 7 (26.9) 19 (73.1) 26 0.391
Primary 1 (9.1) 10 (90.9) 11
Source of fund
Insurance 4 (25) 12 (75) 16
No Insurance 4 (19) 17 (81) 21
Parity
0-1 4 (30.8) 9 (69.2) 13 0.613
≥2 4 (33.3) 8 (66.7) 12
Stage
II 2 (25) 6 (75) 8 0.607
II and IV 7 (22.6) 24 (77.4) 31
Surgery
Complete 5 (38.5) 8 (61.5) 13 0.348
Incomplete 1 (16.7) 5 (83.3) 6
Presurgery hemoglobin level (g/dL)
<10 3 (42.9) 4 (57.1) 7 0.187
≥10 6 (18.8) 26 (81.3) 32
Presurgery albumin level (mg/dL)
≤3.5 4 (21.1) 15 (78.9) 19 0.506
>3.5 4 (26.7) 11 (73.3) 15
Presurgery Ca125 level
≤35 0 (0) 4 (100) 4 0.365
35.1-200 2 (40) 3 (60) 5
>200 4 (23.5) 13 (76.5) 17
Recurrence
Yes 3 (20) 12 (80) 15 0.519
No 3 (37.5) 5 (62.5) 8
Lost to follow up 3 (20) 12 (80) 15
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regimen were 3-4 times higher than those treated with the cisplatin-
based regimen. Treatment costs of ovarian cancer patients based on the 
type of chemotherapy are described in Table 2.
Based on the cumulative survival probability, the patients treated 
with taxane were more likely to have a higher survival probability 
(50%) and longer disease-free duration (median=18 months) than the 
patients who were treated with cisplatin (survival probability = 0%; 
median=5 months). Overall, the results showed that the disease-free 
duration of the patients who received the taxane-based chemotherapy 
was 3 times longer than that of the patients who were treated with the 
cisplatin-based regimen. Cumulative survival probability of ovarian 
cancer patients based on the type of chemotherapy is described in 
Fig. 1. Median disease-free survival based on a 2-year follow-up is 
shown in Table 3.
DISCUSSION
Costs of surgery
The surgery-related cost of ovarian cancer in Indonesia was 
approximately IDR 81 million. This cost was lower than the reported 
cost in the U.S., which was between $200 and $300 million U.S. dollars 
in the years up to and including 2004 [13].
Chemotherapy cost
The mean cost of cisplatin-based chemotherapy in Indonesia was 
IDR 18 million or roughly one-fourth cheaper than that of taxane-
based chemotherapy, which cost IDR 80 million for six cycles. The 
components that contributed to the direct cost of chemotherapy were 
medication, pre- and post-chemotherapy medication, and adverse 
effects, which incurred additional personal or examination costs [13]. 
The incremental cost for taxane-based therapy per life-year saved was 
IDR 95 million or equal to $7,056. Its cost effectiveness was better than 
that reported in Spain ($6,395), France ($6,642), and the U.K. ($ 6,403) 
but poorer than that reported in the Netherlands ($7,796), Germany 
($9,362), and Italy ($ 11,420) [14,15].
The approximate pre- and post-chemotherapy costs of the taxane-based 
therapy, including adverse effects of the treatment, were 6.1 and IDR 
9.6 million, respectively. For the cisplatin-based regimen, these costs were 
IDR 1.8 and 2.4 million, respectively. The pre- and post-chemotherapy 
costs of the taxane-based chemotherapy were 3-4 times higher than 
those incurred with cisplatin-based chemotherapy. According to the 
literature, adverse effects of taxane-based chemotherapy include 
neurotoxicity and hematological disturbances [16].
Although a standard protocol is in place at Dharmais Cancer Hospital for 
ovarian cancer treatment, the doctor’s preference and the procurement 
process, including the price of medications, discounts, and availability, 
lead to variations in the use of ovarian cancer medications. These 
variations result in differences in treatment costs. The procurement 
process for medical materials and equipment at Dharmais Cancer 
Hospital also affect total treatment costs. In this study, the cost included 
the cost of medical materials and equipment used in surgery procedure 
but excluded the cost of medical materials and equipment in the 
chemotherapy procedure because of the insignificant nature of these 
costs as compared to the total cost of medications and medical services.
Reviews on the Health Technology Assessment and clinical pathway 
implementation are expected to improve the efficiency of the service 
by lowering service costs and lengths of hospital stays, in addition to 
improving the quality of the service [17].
Recurrence
Based on a 2-year follow-up, the cumulative survival probability of the 
patients who received the cisplatin-based and taxane-based therapies 
was ±50% and ±40%, respectively, with a lost to follow-up rate of 
34.3%. The mean and median period of recurrence in the taxane-based 
chemotherapy group was 16.6 months and 18 months, respectively. In 
the cisplatin-based chemotherapy group, the mean and median period 
of recurrence was 13.7 months and 5 months, respectively. The results 
for medial survival were similar to those found in the GOG 111-Dutch/
Danish-AGO-GOG 158 study, which reported that the median survival of 
patients who received taxane-based treatment was 16-19.4 months [18]. 
However, the median survival of patients who received cisplatin-based 
treatment in the Dutch/Danish study was different (11.5-13 months).
CONCLUSION
The total cost of taxane-based chemotherapy was 4-5 times higher than 
the cost of cisplatin-based therapy. The mean and median period of 
recurrence were 13.7 months and 5 months, respectively, in the cisplatin-
based group, and it was 16.6 months and 18 months, respectively, in the 
taxane-based group. The probability of non-recurrence in the patients 
who received cisplatin-based chemotherapy was 50%, whereas it was 
42% in the taxane-based group. This study found that a taxane-based 
regimen used as adjuvant chemotherapy was 3 times more protective 
against the recurrence of ovarian cancer as compared to cisplatin-based 
chemotherapy.
Fig. 1: Cumulative survival probability of ovarian cancer patients 
based on the type of chemotherapy
Table 2: Treatment costs of ovarian cancer patients based on the type of chemotherapy
Variables n Cisplatin based % Cost Taxane based % Cost
Surgery 13 Rp. 81.133.836 78 Rp. 81.133.836 45.7
Chemotherapy/6 cycles 12 Rp. 18.822.666 18 Rp. 80.739.390 45.4
Pre-chemotherapy/6 cycles 1 Rp. 1.880.964 2 Rp. 6.130.410 3.5
Post-chemotherapy/6 cycles 1 Rp. 2.436.216 2 Rp. 9.660.432 5.4
Total costs Rp. 104.273.682 100 Rp. 177.664.068 100.0





Cisplatin based (n=6) Taxane based (n=29)
Mean 13.7±4.23 (SE) 16.6±1.6 (SE)
Median 5 (SE, none) 18±4.8 (SE)
SE: Standard error
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